{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:05:45Z","timestamp":1791572745984,"version":"4.3.4"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,15]]},"DOI":"10.2146\/ajhp140157","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T09:32:55Z","timestamp":1409391175000},"page":"1539-1554","source":"Crossref","is-referenced-by-count":65,"title":["The opioid abuse and misuse epidemic: Implications for pharmacists in hospitals and health systems"],"prefix":"10.1093","volume":"71","author":[{"given":"Daniel J.","family":"Cobaugh","sequence":"first","affiliation":[{"name":"ASHP Research and Education Foundation, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Gainor","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Gaston","sequence":"additional","affiliation":[{"name":"UW Health, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai C.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbarajean","family":"Magnani","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Tufts Medical Center, and Professor and Chair, Department of Anatomic and Clinical Pathology, Tufts University School of Medicine, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"McPherson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob T.","family":"Painter","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Krenzelok","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041211192299900_b1-0711539","unstructured":"Centers for Disease Control and Prevention. CDC\u2019s top ten: 5 health achievements in 2013 and 5 health threats in 2014 (December17, 2013). http:\/\/blogs.cdc.gov\/cdcworksforyou24-7\/2013\/12\/cdc%e2%80%99s-top-ten-5-health-achievements-in-2013-and-5-health-threats-in-2014\/ (accessed 2014 Feb 10)."},{"key":"2019041211192299900_b2-0711539","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.36076\/ppj.2008\/11\/S181","article-title":"Effectiveness of opioids in the treatment of chronic non-cancer pain","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"2019041211192299900_b3-0711539","article-title":"Acute pain management: operative or medical procedures and trauma","volume-title":"Clinical practice guideline no. 1","author":"Carr","year":"1992"},{"key":"2019041211192299900_b4-0711539","article-title":"Management of cancer pain","volume-title":"Clinical practice guideline no. 9","author":"Jacox","year":"1994"},{"key":"2019041211192299900_b5-0711539","volume-title":"Guideline for the management of cancer pain in adults and children","author":"Miaskowski","year":"2005"},{"key":"2019041211192299900_b6-0711539","first-page":"2","volume-title":"Principles of analgesic use in the treatment of acute pain and cancer pain","author":"American Pain Society","year":"2008","edition":"6th"},{"key":"#cr-split#-2019041211192299900_b7-0711539.1","unstructured":"2. Chou R Fanciullo GJ Fine PG ., for the American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain (February 2009). www.jpain.org\/article\/S1526-5900"},{"key":"#cr-split#-2019041211192299900_b7-0711539.2","unstructured":"3. 00831-6\/abstract (accessed 2013 Oct 18)."},{"key":"2019041211192299900_b8-0711539","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.biopha.2006.06.012","article-title":"Preemptive analgesia and protective premedication. What is the difference?","volume":"60","author":"Bromley","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"2019041211192299900_b9-0711539","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/ldh030","article-title":"Preemptive analgesia","volume":"71","author":"Dahl","year":"2004","journal-title":"Br Med Bull"},{"key":"2019041211192299900_b10-0711539","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bpa.2006.11.004","article-title":"Do we need preemptive analgesia for the treatment of postoperative pain?","volume":"21","author":"Grape","year":"2007","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"2019041211192299900_b11-0711539","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/BF03020375","article-title":"Preemptive analgesia II: recent advances and current trends","volume":"48","author":"Kelly","year":"2001","journal-title":"Can J Anaesth"},{"key":"2019041211192299900_b12-0711539","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00000542-200203000-00032","article-title":"A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief","volume":"96","author":"M\u00f8iniche","year":"2002","journal-title":"Anesthesiology"},{"key":"2019041211192299900_b13-0711539","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/ACO.0b013e328330373a","article-title":"Multimodal analgesia for controlling acute postoperative pain","volume":"22","author":"Buvanendran","year":"2009","journal-title":"Curr Opin Anaesthesiol"},{"key":"2019041211192299900_b14-0711539","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3949\/ccjm.73.Suppl_1.S72","article-title":"Optimizing postoperative pain management","volume":"73","author":"Ritchey","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"2019041211192299900_b15-0711539","unstructured":"Food and Drug Administration. FDA drug safety communication: safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and\/or adenoidectomy (February20, 2013). www.fda.gov\/Drugs\/Drug-Safety\/ucm339112.htm (accessed 2013 Oct 29)."},{"key":"2019041211192299900_b16-0711539","unstructured":"Food and Drug Administration. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and\/or adenoidectomy. www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM339116.pdf (accessed 2013 Nov 7)."},{"key":"2019041211192299900_b17-0711539","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archsurg.1963.01310180028007","article-title":"Are postoperative narcotics necessary?","volume":"87","author":"Roe","year":"1963","journal-title":"Arch Surg"},{"key":"2019041211192299900_b18-0711539","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1213\/00000539-197101000-00001","article-title":"Studies in pain with the analgesic-demand system","volume":"50","author":"Sechzer","year":"1971","journal-title":"Anesth Analg"},{"key":"2019041211192299900_b19-0711539","first-page":"612145","article-title":"A clinical approach to neuraxial morphine for the treatment of postoperative pain","volume":"2012","author":"Bujedo","year":"2012","journal-title":"Pain Res Treat"},{"key":"2019041211192299900_b20-0711539","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/175045890801801105","article-title":"Managing acute pain in opioid tolerant patients","volume":"18","author":"Bourne","year":"2008","journal-title":"J Perioper Pract"},{"key":"2019041211192299900_b21-0711539","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","article-title":"Acute pain management for patients receiving maintenance methadone or buprenorphine therapy","volume":"144","author":"Alford","year":"2006","journal-title":"Ann Intern Med"},{"key":"2019041211192299900_b22-0711539","volume-title":"Demystifying opioid conversion calculations: a guide for effective dosing","author":"McPherson","year":"2010"},{"key":"2019041211192299900_b23-0711539","doi-asserted-by":"crossref","first-page":"E85","DOI":"10.36076\/ppj.2011\/14\/E85","article-title":"A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain","volume":"14","author":"Colson","year":"2011","journal-title":"Pain Physician"},{"issue":"suppl 2","key":"2019041211192299900_b24-0711539","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"2019041211192299900_b25-0711539","first-page":"252","article-title":"Rational use of opioids for management of chronic nonterminal pain","volume":"86","author":"Berland","year":"2012","journal-title":"Am Fam Physician"},{"key":"2019041211192299900_b26-0711539","unstructured":"Utah Department of Health. Utah clinical guidelines on prescribing opioids for treatment of pain, 2009. http:\/\/health.utah.gov\/prescription\/guidelines.html (accessed 2013 Oct 18)."},{"key":"2019041211192299900_b27-0711539","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"key":"2019041211192299900_b28-0711539","first-page":"411","article-title":"Drug screening by immunoassays","volume-title":"The clinical toxicology laboratory: contemporary practice of poisoning evaluations","author":"Kwong","year":"2013","edition":"2nd"},{"key":"2019041211192299900_b29-0711539","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1373\/clinchem.2010.152124","article-title":"Oral fluid testing: promises and pitfalls","volume":"57","author":"Huestis","year":"2012","journal-title":"Clin Chem"},{"key":"2019041211192299900_b30-0711539","first-page":"447","article-title":"Urine drug testing in opioid therapy for chronic pain management","volume-title":"The clinical toxicology laboratory: contemporary practice of poisoning evaluations","author":"Kwong","year":"2013","edition":"2nd"},{"key":"2019041211192299900_b31-0711539","first-page":"15","article-title":"Supporting the pain service","volume-title":"Clinical toxicology testing: a guide for laboratory professionals","author":"Hammett-Stabler","year":"2012"},{"key":"2019041211192299900_b32-0711539","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids","volume":"81","author":"Somogyi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2019041211192299900_b33-0711539","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jat\/32.4.319","article-title":"Evidence that morphine is metabolized to hydromorphone but not to oxymorphone","author":"Cone","year":"2008","journal-title":"J Analyt Tox"},{"key":"2019041211192299900_b34-0711539","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cca.2010.08.029","article-title":"Anomalous observations of hydrocodone in patients on oxycodone","volume":"412","author":"West","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2019041211192299900_b35-0711539","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/FTD.0b013e3181c1082a","article-title":"Anomalous observations of codeine in patients on morphine","volume":"31","author":"West","year":"2009","journal-title":"Ther Drug Monit"},{"key":"2019041211192299900_b36-0711539","first-page":"1171","article-title":"Overdose deaths involving prescription opioids among Medicaid enrollees\u2014Washington, 2004\u20132007","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR"},{"key":"2019041211192299900_b37-0711539","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","article-title":"National surveillance of emergency department visits for outpatient adverse drug events","volume":"296","author":"Budnitz","year":"2006","journal-title":"JAMA"},{"key":"2019041211192299900_b38-0711539","first-page":"705","article-title":"Emergency department visits involving nonmedical use of selected prescription drugs\u2014United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"2019041211192299900_b39-0711539","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers\u2014United States, 1999\u20132008","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"key":"2019041211192299900_b40-0711539","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"key":"2019041211192299900_b41-0711539","first-page":"869","article-title":"Drug overdose deaths\u2014Florida, 2003\u20132009","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"key":"2019041211192299900_b42-0711539","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"N Engl J Med"},{"key":"2019041211192299900_b43-0711539","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/00007611-199611000-00023","article-title":"Muscle rigidity due to fentanyl infusion in the pediatric patient","volume":"89","author":"Glick","year":"1996","journal-title":"South Med J"},{"key":"2019041211192299900_b44-0711539","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0196-0644(85)80251-1","article-title":"Neurotoxicity of meperidine","volume":"14","author":"Goetting","year":"1985","journal-title":"Ann Emerg Med"},{"key":"2019041211192299900_b45-0711539","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","article-title":"Opioid-induced delay in gastric emptying","volume":"87","author":"Murphy","year":"1997","journal-title":"Anesthesiology"},{"key":"2019041211192299900_b46-0711539","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0196-0644(05)80933-3","article-title":"The empiric use of naloxone in patients with altered mental status: a reappraisal","volume":"20","author":"Hoffman","year":"1991","journal-title":"Ann Emerg Med"},{"key":"2019041211192299900_b47-0711539","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s13181-012-0286-3","article-title":"Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population","volume":"9","author":"Manini","year":"2013","journal-title":"J Med Toxicol"},{"key":"2019041211192299900_b48-0711539","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/PCC.0b013e3181f3a118","article-title":"Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine\/naloxone","volume":"12","author":"Pedapati","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"2019041211192299900_b49-0711539","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2013.06.058","article-title":"Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children","volume":"163","author":"Lavonas","year":"2013","journal-title":"J Pediatr"},{"key":"2019041211192299900_b50-0711539","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1521-0391.2009.00002.x","article-title":"Methadone and buprenorphine toxicity in children","volume":"19","author":"Boyer","year":"2010","journal-title":"Am J Addict"},{"key":"2019041211192299900_b51-0711539","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/18744737112059990010","article-title":"Buprenorphine and buprenorphine\/naloxone intoxication in children\u2014how strong is the risk","volume":"6","author":"Soyka","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"2019041211192299900_b52-0711539","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.annemergmed.2008.07.015","article-title":"The underrecognized toll of prescription opioid abuse on young children","volume":"53","author":"Bailey","year":"2009","journal-title":"Ann Emerg Med"},{"key":"2019041211192299900_b53-0711539","article-title":"Fentanyl mechanism of action and pharmacokinetics [monograph]","volume-title":"Micromedex, version 2.0 [online database]","year":"2013"},{"key":"2019041211192299900_b54-0711539","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jemermed.2011.05.017","article-title":"Whole fentanyl patch ingestion: a multi-center case series","volume":"42","author":"Mrvos","year":"2012","journal-title":"J Emerg Med"},{"key":"2019041211192299900_b55-0711539","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1556-4029.2007.00597.x","article-title":"Oral abuse of fentanyl patches (Duragesic): seven case reports","volume":"53","author":"Woodall","year":"2008","journal-title":"J Forensic Sci"},{"key":"2019041211192299900_b56-0711539","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jemermed.2007.10.075","article-title":"Fentanyl intoxication caused by abuse of transdermal fentanyl","volume":"40","author":"Moon","year":"2011","journal-title":"J Emerg Med"},{"key":"2019041211192299900_b57-0711539","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jemermed.2011.03.011","article-title":"Recurrent respiratory depression associated with fentanyl transdermal patch gel reservoir ingestion","volume":"42","author":"D\u2019Orazio","year":"2012","journal-title":"J Emerg Med"},{"key":"2019041211192299900_b58-0711539","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/PEC.0b013e31825358b4","article-title":"Transdermal fentanyl in deliberate overdose in pediatrics","volume":"28","author":"Lyttle","year":"2012","journal-title":"Pediatr Emerg Care"},{"key":"2019041211192299900_b59-0711539","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1752-1947-6-220","article-title":"Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches: a case report","volume":"6","author":"Sindali","year":"2012","journal-title":"J Med Case Rep"},{"key":"2019041211192299900_b60-0711539","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5055\/jom.2013.0149","article-title":"Pharmacokinetic evaluation of hydrocodone\/acetaminophen for pain management","volume":"9","author":"Singla","year":"2013","journal-title":"J Opioid Manag"},{"key":"2019041211192299900_b61-0711539","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00213-010-1942-4","article-title":"Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies","volume":"212","author":"Stoops","year":"2010","journal-title":"Psychopharmacol"},{"key":"2019041211192299900_b62-0711539","unstructured":"Food and Drug Administration. FDA approves extended-release, single-entity hydrocodone product (October25, 2013). www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm372287.htm (accessed 2014 Jun 4)."},{"key":"2019041211192299900_b63-0711539","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/15563650.2013.848282","article-title":"Fatalities involving acetaminophen combination products reported to United States poison centers","volume":"51","author":"Doyon","year":"2013","journal-title":"Clin Toxicol"},{"key":"2019041211192299900_b64-0711539","first-page":"156","article-title":"Repeated supratherapeutic acetaminophen (paracetamol) use resulting in a fatality","volume":"15","author":"Krenzelok","year":"2011","journal-title":"Ther Pharmacol Clin Toxicol"},{"key":"2019041211192299900_b65-0711539","article-title":"Methadone hydrochloride [monograph]","volume-title":"AHFS DI Essentials [online database]","year":"2013"},{"key":"2019041211192299900_b66-0711539","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/emj.2003.009613","article-title":"Naloxone in opioid poisoning: walking the tightrope","volume":"22","author":"Clarke","year":"2005","journal-title":"Emerg Med J"},{"key":"2019041211192299900_b67-0711539","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jemermed.2012.11.104","article-title":"Medical outcomes associated with nonmedical use of methadone and buprenorphine","volume":"45","author":"Lee","year":"2013","journal-title":"J Emerg Med"},{"key":"2019041211192299900_b68-0711539","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.07.014","article-title":"The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases","volume":"106","author":"Darke","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"2019041211192299900_b69-0711539","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1467-842X.2002.tb00185.x","article-title":"Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines","volume":"26","author":"Caplehorn","year":"2002","journal-title":"Aust N Z J Public Health"},{"key":"2019041211192299900_b70-0711539","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00952990.2013.804525","article-title":"QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study","volume":"39","author":"Fareed","year":"2013","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2019041211192299900_b71-0711539","doi-asserted-by":"crossref","first-page":"221","DOI":"10.12968\/hmed.2007.68.4.221a","article-title":"Methadone-associated QT prolongation and torsades de pointes","volume":"68","author":"Al Sardar","year":"2007","journal-title":"Br J Hosp Med (Lond)"},{"key":"2019041211192299900_b72-0711539","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4088\/PCC.v10n0609","article-title":"Methadone-associated QTc prolongation: a case report and review of the literature","volume":"10","author":"Abramson","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2019041211192299900_b73-0711539","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mpmed.2011.12.028","article-title":"Opioids","volume":"40","author":"Bateman","year":"2011","journal-title":"Medicine"},{"key":"2019041211192299900_b74-0711539","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpain.2005.05.004","article-title":"Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2001\u20132004","volume":"6","author":"Cicero","year":"2005","journal-title":"J Pain"},{"issue":"2","key":"2019041211192299900_b75-0711539","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3810\/pgm.2009.03.1988","article-title":"Oxycontin abuse and overdose","volume":"121","author":"Aquina","year":"2009","journal-title":"Postgrad Med"},{"key":"2019041211192299900_b76-0711539","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1520\/JFS2004194","article-title":"One hundred seventy two deaths involving the use of oxycodone in Palm Beach County","volume":"50","author":"Wolf","year":"2005","journal-title":"J Forensic Sci"},{"key":"2019041211192299900_b77-0711539","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1556-4029.2011.01703.x","article-title":"Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999\u20132008","volume":"56","author":"Darke","year":"2011","journal-title":"J Forensic Sci"},{"key":"2019041211192299900_b78-0711539","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2125.2008.03327.x","article-title":"Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of jERG activity in vitro","volume":"67","author":"Fanoe","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211192299900_b79-0711539","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/qjmed\/hcs176","article-title":"Oxycodone overdose causes naloxone responsive coma and QT prolongation","volume":"106","author":"Berling","year":"2013","journal-title":"QJM"},{"key":"2019041211192299900_b80-0711539","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ajem.2012.10.004","article-title":"Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication","volume":"31","author":"Bauman","year":"2013","journal-title":"Am J Emerg Med"},{"key":"2019041211192299900_b81-0711539","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/10903120903144866","article-title":"Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose","volume":"13","author":"Robertson","year":"2009","journal-title":"Prehosp Emerg Care"},{"key":"2019041211192299900_b82-0711539","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajem.2008.12.009","article-title":"Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses","volume":"28","author":"Merlin","year":"2010","journal-title":"Am J Emerg Med"},{"key":"2019041211192299900_b83-0711539","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2105\/AJPH.2008.146647","article-title":"Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose","volume":"99","author":"Doe-Simkins","year":"2009","journal-title":"Am J Public Health"},{"key":"2019041211192299900_b84-0711539","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"Br Med J"},{"key":"2019041211192299900_b85-0711539","first-page":"577","article-title":"Effectiveness of low dose naloxone to reverse respiratory depression in opioid intoxication","volume":"50","author":"Kim","year":"2012","journal-title":"Clin Toxicol"},{"key":"2019041211192299900_b86-0711539","unstructured":"Food and Drug Administration. FDA approves new hand-held auto-injector to reverse opioid overdose (April03, 2014). www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm391465.htm (accessed 2014 Jul 17)."},{"key":"2019041211192299900_b87-0711539","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1081\/CLT-51867","article-title":"Position paper: single-dose activated charcoal","volume":"43","author":"Krenzelok","year":"2005","journal-title":"Clin Toxicol"},{"key":"2019041211192299900_b88-0711539","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s13181-012-0274-7","article-title":"Laboratory testing for prescription opioids","volume":"8","author":"Milone","year":"2012","journal-title":"J Med Toxicol"},{"key":"2019041211192299900_b89-0711539","first-page":"65","article-title":"Diversion of prescription drugs to the black market: what the states are doing to curb the tide","volume":"27","author":"Forgione","year":"2001","journal-title":"J Health Care Finance"},{"key":"2019041211192299900_b90-0711539","unstructured":"Food and Drug Administration. FDA announces safety labeling changes and postmarketing study requirements for extended-release and long-acting opioid analgesics (September10, 2013). www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm367726.htm (accessed 2014 Jul 17)."},{"key":"2019041211192299900_b91-0711539","unstructured":"National Alliance for Model State Drug Laws. Status of state prescription drug monitoring programs (July2013). www.namsdl.org\/library\/13999269-1C23-D4F9-74EF032677373B17 (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b92-0711539","unstructured":"National Alliance for Model State Drug Laws. Prescription drug monitoring programs: a brief overview (March2011). www.namsdl.org\/library\/2C1D3D84-1372-636C-DD7AA3FC63B30DB9\/ (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b93-0711539","unstructured":"National Alliance for Model State Drug Laws. Status of state prescription drug monitoring programs (PDMPs). www.namsdl.org\/library\/1E4808C8-1372-636C-DD0293F829471A7E\/ (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b94-0711539","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1526-4637.2011.01062.x","article-title":"Prescription drug monitoring programs and death rates from drug overdose","volume":"12","author":"Paulozzi","year":"2011","journal-title":"Pain Med"},{"key":"2019041211192299900_b95-0711539","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1526-4637.2012.01327.x","article-title":"Do prescription monitoring programs impact state trends in opioid abuse\/misuse?","volume":"13","author":"Reifler","year":"2012","journal-title":"Pain Med"},{"key":"2019041211192299900_b96-0711539","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/15360288.2012.738288","article-title":"The use of prescription monitoring programs to reduce opioid diversion and improve patient safety","volume":"27","author":"Morgan","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2019041211192299900_b97-0711539","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annemergmed.2009.12.011","article-title":"A state-wide prescription monitoring program affects emergency department prescribing behaviors","volume":"56","author":"Baehren","year":"2010","journal-title":"Ann Emerg Med"},{"key":"2019041211192299900_b98-0711539","unstructured":"Prescription Drug Monitoring Program Center of Excellence. Keeping patients safe: a case study on using prescription monitoring program data in an outpatient addictions treatment setting (March2011). www.pdmpexcellence.org\/sites\/all\/pdfs\/methadone_treatment_nff_%203_2_11.pdf (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b99-0711539","unstructured":"Prescription Drug Monitoring Program Center of Excellence. Prescription drug monitoring programs: an assessment of the evidence for best practices (September20, 2012). www.pdmpexcellence.org\/sites\/all\/pdfs\/Brandeis_PDMP_Report_final.pdf (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b100-0711539","unstructured":"Blumenschein K Fink JL Freeman PR ., for the KASPER Evaluation Team. Independent evaluation of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). http:\/\/chfs.ky.gov\/NR\/rdonlyres\/24493B2E-B1A1-4399-89AD-1625953BAD43\/0\/KASPEREvaluationFinalReport10152010.pdf (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b101-0711539","unstructured":"General Accounting Office. Prescription drugs: state monitoring programs may help to reduce illegal diversion. Testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives (March04, 2004). www.gao.gov\/new.items\/d04524t.pdf (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b102-0711539","doi-asserted-by":"crossref","first-page":"430","DOI":"10.18553\/jmcp.2011.17.6.430","article-title":"Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances","volume":"17","author":"Fass","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"2019041211192299900_b103-0711539","unstructured":"Trust for America\u2019s Health. Prescription drug abuse: strategies to stop the epidemic (October07, 2013). http:\/\/healthy-americans.org\/reports\/drugabuse2013\/ (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b104-0711539","unstructured":"National Alliance for Model State Drug Laws. Components of a strong prescription drug monitoring (PMP) program\/statute (revised June 2012). www.namsdl.org\/library\/85740FEB-19B9-E1C5-31AA3E9A59034388\/ (accessed 2013 Oct 31)."},{"key":"2019041211192299900_b105-0711539","unstructured":"Institute for Safe Medication Practices. ISMP\u2019s list of high-alert medications. www.ismp.org\/Tools\/institutionalhighAlert.asp (accessed 2013 Oct 25)."},{"key":"2019041211192299900_b106-0711539","first-page":"32","volume-title":"Principles of analgesic use in the treatment of acute pain and cancer pain","author":"American Pain Society","year":"2008","edition":"6th"},{"key":"2019041211192299900_b107-0711539","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00045391-200201000-00010","article-title":"Meperidine: a critical review","volume":"9","author":"Latta","year":"2002","journal-title":"Am J Ther"},{"key":"2019041211192299900_b108-0711539","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpainsymman.2012.08.013","article-title":"Opioid therapies and cytochrome p450 interactions","volume":"44","author":"Gudin","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"2019041211192299900_b109-0711539","doi-asserted-by":"crossref","first-page":"e1343","DOI":"10.1542\/peds.2011-2538","article-title":"More codeine fatalities after tonsillectomy in North American children","volume":"129","author":"Kelly","year":"2012","journal-title":"Pediatrics"},{"issue":"suppl 2","key":"2019041211192299900_b110-0711539","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1111\/j.1526-4637.2011.01128.x","article-title":"Project Lazarus: community-based overdose prevention in rural North Carolina","volume":"12","author":"Albert","year":"2011","journal-title":"Pain Med"},{"key":"2019041211192299900_b111-0711539","unstructured":"Community Care of North Carolina. www.communitycarenc.com\/media\/related-downloads\/pl-toolkit-eds.pdf (accessed 2013 Oct 21)."},{"key":"2019041211192299900_b112-0711539","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1526-4637.2007.00401.x","article-title":"Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department","volume":"9","author":"Wilsey","year":"2008","journal-title":"Pain Med"},{"key":"2019041211192299900_b113-0711539","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/AJP.0b013e3180330dc5","article-title":"Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain","volume":"23","author":"Wasan","year":"2007","journal-title":"Clin J Pain"},{"key":"2019041211192299900_b114-0711539","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drugalcdep.2010.05.017","article-title":"Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study","volume":"112","author":"Edlund","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"2019041211192299900_b115-0711539","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1001\/archinte.166.19.2087","article-title":"Association between mental health disorders, problem drug use, and regular prescription opioid use","volume":"166","author":"Sullivan","year":"2006","journal-title":"Arch Intern Med"},{"key":"2019041211192299900_b116-0711539","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7326\/M13-2209","article-title":"Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians","volume":"160","author":"Kirschner","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019041211192299900_b117-0711539","unstructured":"Joint Commission. Sentinel event alert issue 49: safe use of opioids in hospitals (August08, 2012). www.jointcommission.org\/sea_issue_49\/ (accessed 2013 Apr 13)."},{"key":"2019041211192299900_b118-0711539","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMp1308222","article-title":"Abusive prescribing of controlled substances\u2014a pharmacy view","volume":"369","author":"Betses","year":"2013","journal-title":"N Engl J Med"},{"key":"2019041211192299900_b119-0711539","unstructured":"Office of Diversion Control, Drug Enforcement Administration.An informational outline of the Controlled Substances Act (revised 2010). www.deadiversion.usdoj.gov\/pubs\/manuals\/pharm2\/ (accessed 2013 Oct 26)."},{"key":"2019041211192299900_b120-0711539","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.mayocp.2012.03.013","article-title":"Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention","volume":"87","author":"Berge","year":"2012","journal-title":"Mayo Clin Proc"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/18\/1539\/28373446\/ajhp1539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:21:46Z","timestamp":1650068506000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/18\/1539\/5111026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":121,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,9,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140157","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,15]]},"published":{"date-parts":[[2014,9,15]]}}}